RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Taysha Gene Therapies Stock

Taysha Gene Therapies Stocks 2024

Taysha Gene Therapies Stocks

116.12 M

Ticker

TSHA

ISIN

US8776191061

WKN

A2QCJL

In 2024, Taysha Gene Therapies had 116.12 M outstanding stocks, a 0% change from the 116.12 M stocks in the previous year.

The Taysha Gene Therapies Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e116.12
2028e116.12
2027e116.12
2026e116.12
2025e116.12
2024e116.12
2023116.12
202243.95
202137.65
202034.52
201934.52

Taysha Gene Therapies shares outstanding

The number of shares was Taysha Gene Therapies in 2023 — This indicates how many shares 116.121 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Taysha Gene Therapies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Taysha Gene Therapies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Taysha Gene Therapies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Taysha Gene Therapies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Taysha Gene Therapies Aktienanalyse

What does Taysha Gene Therapies do?

Taysha Gene Therapies Inc. is a biopharmaceutical company based in Dallas, Texas, focused on discovering and developing gene therapies for severe neurological disorders. The company was founded in 2019 by leading pharmaceutical entrepreneur RA Capital Management and gene therapy developer Dr. Steven Gray. Taysha Gene Therapies' business model is based on the belief that gene therapy has the potential to revolutionize medicine. The company is dedicated to developing gene therapies that can be used to treat rare genetic diseases, particularly pediatric diseases that have had limited or no treatment options. Their goal is to create innovative therapeutic approaches to improve the lives of affected patients and their families. To achieve this, the company conducts extensive research and development work, addressing the challenging questions and challenges in their field. The biggest hurdle in gene therapy development is the need to tailor treatments to the specific defects of individual patients, requiring personalized therapy. Taysha Gene Therapies addresses this issue through the use of AAV gene therapies, which provide a versatile tool and allow the company to diversify. Currently, the company has four different divisions focused on developing gene therapies for rare diseases. Their first priority is TSHA-101, a gene therapy targeting Angelman syndrome, a genetic disorder that occurs in babies and toddlers and can cause epileptic seizures, developmental delays, sleep disorders, and speech problems. Taysha Gene Therapies is also working on therapies for Tay-Sachs and GM1 gangliosidosis, which are also rare and severe diseases. Additionally, the company is developing therapies for Rett syndrome. Taysha Gene Therapies aims to make global progress in the field of neuropsychiatric and neurological disorders by setting new standards and creating innovative concepts. The company collaborates with leading geneticists, scientists, and neurologists to incorporate the latest technologies in gene therapy development. They have the potential to elevate the treatment of rare genetic diseases that have had limited or no treatment options. In their efforts to improve patient care, Taysha Gene Therapies has formed partnerships with other companies and institutions. In March 2020, they established partnerships with UT Southwestern, RCPD, and AveXis to facilitate the exchange of data and expertise on selected treatment options. This collaboration aims to accelerate progress in gene therapy and develop new therapies and technologies that enhance patient treatment and quality of life. Overall, Taysha Gene Therapies is engaged in exciting and innovative work focused on implementing gene therapies for rare genetic diseases. With their innovative approaches to therapy concept development, partnerships with leading institutions, and excellent collaboration with other companies, they aim to make a significant contribution to improving healthcare. Output: Taysha Gene Therapies Inc. is a biopharmaceutical company based in Dallas, Texas. It focuses on discovering and developing gene therapies for severe neurological disorders, particularly rare genetic diseases in children. The company aims to improve the lives of patients and their families through innovative therapies. It collaborates with experts and uses cutting-edge technologies. Taysha Gene Therapies also partners with other organizations to accelerate progress and improve patient care. Its mission is to revolutionize medicine and contribute to healthcare improvement. Taysha Gene Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Taysha Gene Therapies's Shares Outstanding

Taysha Gene Therapies's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Taysha Gene Therapies’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Taysha Gene Therapies’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Taysha Gene Therapies’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Taysha Gene Therapies stock

How many stocks are there of Taysha Gene Therapies?

The current number of stocks of Taysha Gene Therapies is 116.12 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Taysha Gene Therapies are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Taysha Gene Therapies evolved in recent years?

The number of shares of Taysha Gene Therapies has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Taysha Gene Therapies as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Taysha Gene Therapies?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Taysha Gene Therapies pay?

Over the past 12 months, Taysha Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Taysha Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Taysha Gene Therapies?

The current dividend yield of Taysha Gene Therapies is .

When does Taysha Gene Therapies pay dividends?

Taysha Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Taysha Gene Therapies?

Taysha Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Taysha Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Taysha Gene Therapies located?

Taysha Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taysha Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taysha Gene Therapies from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Taysha Gene Therapies pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Taysha Gene Therapies in the year 2023?

In the year 2023, Taysha Gene Therapies distributed 0 USD as dividends.

In which currency does Taysha Gene Therapies pay out the dividend?

The dividends of Taysha Gene Therapies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Taysha Gene Therapies

Our stock analysis for Taysha Gene Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taysha Gene Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.